# Novel Microdevices

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novel-microdevices

- Industry: Medical Devices & Equipment
- Headquarters: Baltimore, US
- Website: www.noveldx.com
- Total disclosed funding: $0.5M
- Latest round: Series A (Feb 18, 2025)
- Investors on record: 2

## About

Based in Maryland, US, and founded in 2016 by Andrea Pais (CEO) and Rohan Pais, Novel Microdevices operates as a developer and manufacturer of medical devices intended to facilitate molecular diagnostics.In February 2025, Novel Microdevices, Inc. raised USD 500,000 million in venture funding from new investor Maryland Technology Development Corporation, with participation from returning investor TEDCO. The firm develops and commercializes its proprietary Point-of-Care (POC) rapid molecular diagnostics system called Novel Dx that implements polymerase chain reaction (PCR) technology on a disposable cartridge to diagnose the genetic sequence of cells to identify the disease and the presence of genetic mutations that makes bacteria resistant to antibiotics. The firm diagnoses sexually transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae using vaginal swabs or urine samples.

The company will use the February 2025 funding to support the development and distribution of its product in the healthcare industry.

## Funding rounds

- Series A, Feb 18, 2025, $0.5M — Maryland Technology Development Corporation, TEDCO

## Investors

- Maryland Technology Development Corporation — Series A
- TEDCO (https://capitalatlas.ai/funds/tedco) — Series A